More reads
- Top U.S. medical centers roll out DNA sequencing clinics for healthy (and often wealthy) clients. (STAT)
- Warning signs were always there for Novartis’s AveXis deal. (EP Vantage)
- Regeneron's great science led to an important drug. But will it flop commercially? (Forbes)
- Nuclear pharmacies sue a key supplier of radiology medicines for pursuing an ‘illegal monopoly.’ (STAT Plus)
No hay comentarios:
Publicar un comentario